A rare peek into drug company documents reveals troubling differences between publicly available information and materials the company holds close to its chest. In comparing public and private descriptions of drug trials conducted by pharmaceutical giant Pfizer, researchers discovered discrepancies including changes in the number of study participants and inconsistent definitions of protocols and analyses. [....]
The study's results, published January 29 in PLOS Medicine, show that publications about drug trials don’t always reflect the research that was conducted, says Lisa Bero of the University of California, San Francisco, an expert in methods to assess bias in scientific publishing “We know that entire studies don’t get published and that what does get published is more likely to make a drug look favorable,” she says. “This adds another layer.” [.....]
Comments
Great find, artappraiser.
by Orion on Thu, 01/31/2013 - 1:48pm
I did think you, among others,. might find it useful....
by artappraiser on Fri, 02/01/2013 - 12:40am